Dissecting the gene patent debate

Presented by

LexisNexis and Managing IP

About this talk

The US Court of Appeals for the Federal Circuit issued its decision in Association for Molecular Pathology v USPTO and Myriad Genetics on July 29, reaffirming that isolated DNA sequences are patent eligible. However, if taken up by the Supreme Court, the case could still reverse 35 years of USPTO practice during which the Office has granted thousands of patents on isolated DNA sequences. Join us for a discussion of the case from both the reasearch community and patent holder perspectives, and for a legal analysis of possible next steps. Speakers: Eric Bensen - Author and consultant Lawrence Sung - University of Maryland School of Law Andrew Strong - Kalon Biotherapeutics

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (85)
Subscribers (11222)
‘What keeps in-house counsel awake at night?’ is one way to summarise our editorial focus. We aim to track the strategies of in-house IP counsel within companies, big and small, by speaking directly to them about the day-to-day issues they face. Law firms need practical information that they can apply when advising their clients, and companies find value in benchmarking their strategies with those of their peers. This is why we have adopted this approach in our subscription-based service. Our content is not reactionary or news-focused, but informed and actionable. In this pursuit of in-house intelligence, we also publish several surveys each year that include exclusive data focusing on specific industry issues. These polls allow us to provide an accurate snapshot of how in-house counsel perceive and act on a given issue. Our other core objective is interviewing senior judges, whose insight is valuable for many IP stakeholders. We find that the judiciary are vital for giving counsel, private and in-house, highly useful information for when they are locked in litigation. We continue to speak regularly with IP offices too. Regardless of its specific intent, our coverage is global and encompasses (but is not limited to) the following areas: Copyright; Data; Designs; Patents; Trademarks; and Trade secrets